AFLIBERCEPT

Brand name:

• Eylea®

Pharmaceutical company:

Bayer Australia Ltd

Condition/indication:
(therapeutic use)

• Diabetic macular oedema

PBAC Submission type:

New PBS listing (Category 2)

Comment:

To be considered at a future PBAC meeting

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Not Applicable (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---